Free-text search
Articles per year:
Content Types
-
Pfizer secures $1.5 billion to develop obesity drug
Following the high-profile bidding war with Novo Nordisk over Metsera, Pfizer is taking the next step in its obesity strategy. Investment firm Blackstone will now provide up to $1.5 billion to finance the development of a drug designed to be administered once a month.
-
FDA approves Bayer’s first-in-class stroke drug
The US Food and Drug Administration (FDA) has approved a new type of medicine to reduce the risk of recurrent stroke.
-
Boehringer doubles down on China with $7.4 billion deal
Boehringer Ingelheim continues to strengthen its ties with China’s growing pharmaceutical industry. The German pharmaceutical giant has now signed an agreement with Sino Biopharmaceutical covering six cancer programmes, with a potential value of nearly $7.4 billion.
-
Lytix reports positive cancer data – plans larger trial
Norwegian biotech company Lytix Biopharma has reported positive phase II results for its drug candidate ruxotemitide in melanoma. The company is now aiming for a randomised phase III trial.
-
SynAct Pharma signs first dengue drug deal
SynAct Pharma has entered into its first commercial partnership for resomelagon as a potential treatment for dengue fever.
-
Xbrane wins long-awaited FDA approval for eye drug biosimilar
After a long and winding road, Xbrane has now received FDA approval for Lucamzi, a biosimilar to the eye drug Lucentis.
-
New lung cancer combo shown to extend survival by eight months
A new drug combination extended survival by more than eight months in patients with extensive-stage small cell lung cancer, according to a late-stage clinical trial.
-
Enhertu wins EU approval in early breast cancer
AstraZeneca’s Enhertu is moving into earlier-stage breast cancer treatment after winning EU approval. In a phase III trial, the drug reduced the risk of invasive disease recurrence or death by 53 per cent compared with the current standard treatment.
-
Roche scores phase III win with lung cancer drug
Roche’s investigational cancer drug divarasib reduced the risk of death by 44 per cent compared with existing treatments in a phase III trial involving patients with lung cancer.
-
Early gene therapy offers hope for some ALS patients
New treatments for ALS are raising hopes among researchers. “The earlier a patient receives targeted gene therapy, the greater their chances of living longer,” says Caroline Ingre, who heads ALS research at Karolinska Institutet in Sweden.
-
AstraZeneca’s ADC candidate beats expectations – new phase III data at ESMO
AstraZeneca’s experimental cancer treatment sone-ve delivered longer survival than analysts had expected in a phase III trial in advanced gastric cancer. The company also presented positive results for a combination with Imfinzi in bladder cancer
-
AstraZeneca wins new FDA approval for serious kidney disease
A new treatment indication has opened up for AstraZeneca’s Ultomiris following positive results from a phase III trial. The FDA has approved the drug for a rare kidney disease, although its long-term clinical benefits have yet to be established.
-
Roche doubles down on Chinese biotech in deal worth up to $15 billion
A year after their first antibody-drug conjugate deal, Roche and China’s Hansoh Pharmaceutical are expanding their partnership. The new agreement covers several cancer programmes and could bring Hansoh more than $15 billion in payments.
-
Merck KGAA to acquire Silence Therapeutics for billions
German pharmaceutical and chemical group Merck KGAA has entered into an agreement to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion, equivalent to SEK 12.9 billion.
-
Bristol Myers Squibb reports dual Phase III success
Bristol Myers Squibb has reported positive late-stage results for drug candidates targeting idiopathic pulmonary fibrosis and neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).
-
Camurus takes next step with Oczyesa – wins Canadian approval
Swedish pharmaceutical company Camurus has secured another marketing approval for its acromegaly treatment. Canada has now approved Oczyesa XR, which patients can inject themselves once a month.
-
Pfizer wins new FDA approval for Tukysa in breast cancer
Pfizer is strengthening its position in HER2-positive breast cancer. The FDA has approved Tukysa as a first-line maintenance treatment after a phase III trial showed that the combination extended progression-free survival by 8.6 months.
-
Roche's Tecentriq gets FDA nod after strong colon cancer data
A combination of Tecentriq and chemotherapy cut the risk of recurrence or death by half in patients with stage III colon cancer and dMMR tumours. The results have now paved the way for a new FDA approval.
-
Nobel laureate’s CRISPR biotech shuts down as funding runs out
Caribou Biosciences was one of the early companies to embrace CRISPR gene-editing technology. Now, the biotech is being forced to halt development of its cancer therapies, despite having a candidate ready for phase III.
-
Alligator slims down as new CEO takes over
Alligator Bioscience has appointed Johan Giléus as its new CEO, succeeding Søren Bregenholt, who will leave the company at the end of the year.
-
Phase III goals met – yet Zealand shares fall
Despite meeting both primary endpoints in a Phase 3 trial of the obesity drug survodutide, Zealand Pharma’s shares fell sharply on Thursday.
-
Sanofi strikes another multibillion-dollar deal – four candidates in focus
Sanofi and Regeneron are stepping up their long-standing partnership. The companies are now investing in four new antibody drugs in a deal that could be worth up to $8 billion.
-
Swedish obesity challenger halts drug programme
Swedish biotech company Empros Pharma is discontinuing its obesity drug programme. Difficulties in securing funding and growing competition from GLP-1 drugs are cited as the reasons.
-
Kodiak shares more than double after positive eye drug results
A successful Phase III trial in age-related macular degeneration sent shares in US-based Kodiak Sciences soaring on Monday.
BREAKING